NurExone Biologic Inc.
NRXBF
$0.40
$0.000.40%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.75% | 17.35% | 41.77% | 43.54% | 43.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.21% | 26.23% | 52.61% | 52.69% | 49.97% |
| Operating Income | -10.21% | -26.23% | -52.61% | -52.69% | -49.97% |
| Income Before Tax | -11.61% | -26.59% | -54.35% | -52.58% | -50.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.61% | -26.59% | -54.35% | -52.58% | -50.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.61% | -26.59% | -54.35% | -52.58% | -50.35% |
| EBIT | -10.21% | -26.23% | -52.61% | -52.69% | -49.97% |
| EBITDA | -8.91% | -24.56% | -50.95% | -51.71% | -49.37% |
| EPS Basic | 8.28% | -3.54% | -20.47% | -11.04% | -3.88% |
| Normalized Basic EPS | 8.40% | -3.23% | -20.44% | -11.04% | -4.08% |
| EPS Diluted | 8.28% | -3.54% | -20.47% | -11.04% | -3.88% |
| Normalized Diluted EPS | 8.40% | -3.23% | -20.44% | -11.04% | -4.08% |
| Average Basic Shares Outstanding | 23.08% | 24.50% | 29.79% | 35.46% | 41.06% |
| Average Diluted Shares Outstanding | 23.08% | 24.50% | 29.79% | 35.46% | 41.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |